<?xml version='1.0' encoding='utf-8'?>
<document id="24050970"><sentence text="Pharmacokinetic interactions between eperisone hydrochloride and aceclofenac: a randomized, open-label, crossover study of healthy Korean men."><entity charOffset="37-60" id="DDI-PubMed.24050970.s1.e0" text="eperisone hydrochloride" /><entity charOffset="65-76" id="DDI-PubMed.24050970.s1.e1" text="aceclofenac" /><pair ddi="false" e1="DDI-PubMed.24050970.s1.e0" e2="DDI-PubMed.24050970.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24050970.s1.e0" e2="DDI-PubMed.24050970.s1.e1" /></sentence><sentence text="Eperisone hydrochloride, a centrally acting muscle relaxant, is a calcium antagonist that causes vasodilation and antispastic actions"><entity charOffset="0-23" id="DDI-PubMed.24050970.s2.e0" text="Eperisone hydrochloride" /><entity charOffset="66-73" id="DDI-PubMed.24050970.s2.e1" text="calcium" /><pair ddi="false" e1="DDI-PubMed.24050970.s2.e0" e2="DDI-PubMed.24050970.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24050970.s2.e0" e2="DDI-PubMed.24050970.s2.e1" /></sentence><sentence text=" Aceclofenac, an anti-inflammatory analgesic and antipyretic drug, has similar efficacy and improved gastrointestinal tolerance compared with other nonsteroidal anti-inflammatory drugs, such as diclofenac"><entity charOffset="1-12" id="DDI-PubMed.24050970.s3.e0" text="Aceclofenac" /><entity charOffset="194-204" id="DDI-PubMed.24050970.s3.e1" text="diclofenac" /><pair ddi="false" e1="DDI-PubMed.24050970.s3.e0" e2="DDI-PubMed.24050970.s3.e0" /><pair ddi="false" e1="DDI-PubMed.24050970.s3.e0" e2="DDI-PubMed.24050970.s3.e1" /></sentence><sentence text=" Although eperisone hydrochloride and aceclofenac are frequently coadministered, no published studies have reported on the pharmacokinetic interactions between these 2 drugs"><entity charOffset="10-33" id="DDI-PubMed.24050970.s4.e0" text="eperisone hydrochloride" /><entity charOffset="38-49" id="DDI-PubMed.24050970.s4.e1" text="aceclofenac" /><pair ddi="false" e1="DDI-PubMed.24050970.s4.e0" e2="DDI-PubMed.24050970.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24050970.s4.e0" e2="DDI-PubMed.24050970.s4.e1" /></sentence><sentence text="" /><sentence text="The aim of this study was to investigate any pharmacokinetic interactions between eperisone hydrochloride and aceclofenac in healthy Korean men"><entity charOffset="82-105" id="DDI-PubMed.24050970.s6.e0" text="eperisone hydrochloride" /><entity charOffset="110-121" id="DDI-PubMed.24050970.s6.e1" text="aceclofenac" /><pair ddi="false" e1="DDI-PubMed.24050970.s6.e0" e2="DDI-PubMed.24050970.s6.e0" /><pair ddi="false" e1="DDI-PubMed.24050970.s6.e0" e2="DDI-PubMed.24050970.s6.e1" /></sentence><sentence text="" /><sentence text="This was a randomized, open-label, crossover study" /><sentence text=" Each participant was randomly assigned to 1 of 6 treatment sequences and received eperisone hydrochloride (3 doses of 50 mg each), aceclofenac (2 doses of 100 mg each), or both as a single dose with a 7-day washout period between each dose"><entity charOffset="83-106" id="DDI-PubMed.24050970.s9.e0" text="eperisone hydrochloride" /><entity charOffset="132-143" id="DDI-PubMed.24050970.s9.e1" text="aceclofenac" /><pair ddi="false" e1="DDI-PubMed.24050970.s9.e0" e2="DDI-PubMed.24050970.s9.e0" /><pair ddi="false" e1="DDI-PubMed.24050970.s9.e0" e2="DDI-PubMed.24050970.s9.e1" /></sentence><sentence text=" Blood samples were collected ≤ 24 hours after dosing, and plasma eperisone hydrochloride and aceclofenac concentrations were determined using validated LC/MS-MS"><entity charOffset="66-89" id="DDI-PubMed.24050970.s10.e0" text="eperisone hydrochloride" /><entity charOffset="94-105" id="DDI-PubMed.24050970.s10.e1" text="aceclofenac" /><pair ddi="false" e1="DDI-PubMed.24050970.s10.e0" e2="DDI-PubMed.24050970.s10.e0" /><pair ddi="false" e1="DDI-PubMed.24050970.s10.e0" e2="DDI-PubMed.24050970.s10.e1" /></sentence><sentence text=" Pharmacokinetic analyses were conducted using noncompartmental methods" /><sentence text=" A safety profile was determined using the measurement of vital signs, ECG, and clinical laboratory tests" /><sentence text="" /><sentence text="A total 24 of men were enrolled, and all completed the study" /><sentence text=" The geometric mean ratios (90% CIs) of the Cmax and AUC0-∞ values for eperisone were 1"><entity charOffset="71-80" id="DDI-PubMed.24050970.s15.e0" text="eperisone" /></sentence><sentence text="18 (0" /><sentence text="828-1" /><sentence text="673) and 1" /><sentence text="12 (0" /><sentence text="836-1" /><sentence text="507), respectively" /><sentence text=" The geometric mean ratios (90% CIs) of the Cmax and AUC0-∞ for aceclofenac were 0" /><sentence text="93 (0" /><sentence text="847-1" /><sentence text="022) and 1" /><sentence text="01 (0" /><sentence text="979-1" /><sentence text="036), respectively" /><sentence text=" A total of 7 adverse events were reported in 7 men" /><sentence text=" All adverse events were mild, and no significant differences were found between treatment groups" /><sentence text="" /><sentence text="No clinically significant pharmacokinetic differences exist between 150 mg eperisone hydrochloride and 200 mg aceclofenac when administrated as a monotherapy or in combination"><entity charOffset="75-98" id="DDI-PubMed.24050970.s32.e0" text="eperisone hydrochloride" /><entity charOffset="110-121" id="DDI-PubMed.24050970.s32.e1" text="aceclofenac" /><pair ddi="false" e1="DDI-PubMed.24050970.s32.e0" e2="DDI-PubMed.24050970.s32.e0" /><pair ddi="false" e1="DDI-PubMed.24050970.s32.e0" e2="DDI-PubMed.24050970.s32.e1" /></sentence><sentence text="" /></document>